Could a diaphragm pacemaker help failing hearts?
NCT ID NCT05592392
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This pilot study tested a device that stimulates the diaphragm in time with the heartbeat to see if it can improve heart function in people with heart failure. 35 participants with reduced ejection fraction received the implant. The study checked for safety and changes in heart size and exercise ability.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Synchronized Diaphragmatic Stimulation (SDS) device
- What this could lead to
- If it works, this could offer a new way to improve heart function and quality of life for people with heart failure.
- What could go wrong
- This is a small, early feasibility study with only 35 participants. The device requires surgery and carries risks like infection or breathing problems. Results may not apply to all heart failure patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
35 people
The number who actually took part.
- Started
-
Aug 2022
- Finished
-
Feb 2025
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * NYHA classes II/III on optimal Guideline Directed Medical Therapy * QRS duration ≤ 130 ms * LVEF \< 40% * Willing and able to comply with protocol requirements, including attending all required visits * Wiling to participate in the study and able to sign an informed consent form Exclusion Criteria: * Baseline 6-minute walk test \> 500 meters or \< 200 meters * NT-proBNP\< 250 if on loop diuretics, or NT-proBNP \< 500 if not on loop diuretics * Supine resting heart rate \> 140 bpm * Systolic blood pressure \< 80 mmHg or \> 170 mmHg * Serum creatinine \> 2.5 mg/dL * Serum hepatic function 3x ULN * Unstable angina, AMI, CABG, PTCA, CVA/TIA, persistent AF, NSVT or DCCV within 3 months * Intermittent IV inotropic drug treatment * Arrhythmias present during screening (profound ectopy, bradycardia, profound prevalence of ectopy, NSVT, VF, AF\*, SVT or AFLT) - \* see enrollment exception allowing for 10 patients in AF for a separate subgroup analysis * Reversible non-ischemic cardiomyopathy * Primary valvular disease * Severe primary pulmonary disease, including pulmonary arterial hypertension. PAP sys \>70 mmHg at rest * Severe COPD, other respiratory or lung diseases where FEV \< 50% * Pericardial disease * Diabetic neuropathy * Existing diaphragmatic stimulation for respiration assist * LVAD or other mechanical cardiac assist devices * Contraindications to laparoscopic access to the diaphragm, as determined by the implanting physician * Known intra-abdominal pathology which could increase the risk of laparoscopic access to the diaphragm. * Previous open laparotomy within 1 year * Previous thoracic or abdominal organ transplant * Drug induced immuno-suppression * Body mass index \> 40 * Enrollment in a concurrent investigation / clinical study * Having a life expectancy of \<1 year due to any condition * Pregnant or planning a pregnancy during the study period
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Heart failure with reduced ejection fraction are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Republican Specialized Scientific and Practical Medical Center for Surgery n.a. V. Vakhidov
Tashkent, 100115, Uzbekistan
-
Tbilisi Heart And Vascular Clinic
Tbilisi, 0159, Georgia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a handheld ultrasound help clinics spot heart failure sooner?
- Can yoga classes rival standard rehab for a failing heart?
- Heart failure drug probed for hidden benefit on lung pressure
- Can a heart rate drug keep heart failure patients out of the hospital?
- Nerve-stimulating implant tested for easing heart failure symptoms
- A Body-Scan test may reveal hidden fluid buildup, guiding early diuretic use